Press coverage about United Therapeutics (NASDAQ:UTHR) has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. United Therapeutics earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.9647920058204 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:
- Martine A. Rothblatt Sells 21,512 Shares of United Therapeutics Co. (UTHR) Stock (americanbankingnews.com)
- United Therapeutics buys two D.C. buildings for $6.5M for ‘potential future expansion’ (bizjournals.com)
- Cowen Reaffirms Hold Rating for United Therapeutics (UTHR) (americanbankingnews.com)
- United Therapeutics Co. (UTHR) Given Consensus Rating of “Hold” by Analysts (americanbankingnews.com)
- Insider Selling: United Therapeutics Co. (UTHR) CEO Sells 22,059 Shares of Stock (americanbankingnews.com)
A number of brokerages have recently weighed in on UTHR. Credit Suisse Group raised shares of United Therapeutics from an “underperform” rating to a “neutral” rating and set a $115.00 price objective on the stock in a report on Tuesday. BidaskClub upgraded shares of United Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, March 24th. ValuEngine downgraded shares of United Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, February 27th. Barclays restated an “underweight” rating and set a $105.00 target price (down from $115.00) on shares of United Therapeutics in a research report on Thursday, February 22nd. Finally, Zacks Investment Research upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating and set a $160.00 target price for the company in a research report on Monday, January 15th. Four equities research analysts have rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the company. United Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $135.20.
United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $3.89 earnings per share for the quarter, topping analysts’ consensus estimates of $3.59 by $0.30. The business had revenue of $464.70 million during the quarter, compared to the consensus estimate of $420.55 million. United Therapeutics had a net margin of 24.22% and a return on equity of 24.41%. The company’s revenue was up 13.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $4.12 earnings per share. equities research analysts forecast that United Therapeutics will post 12.46 EPS for the current year.
In other United Therapeutics news, CEO Martine A. Rothblatt sold 43,025 shares of the company’s stock in a transaction dated Friday, March 16th. The shares were sold at an average price of $111.11, for a total value of $4,780,507.75. Following the completion of the transaction, the chief executive officer now owns 21,652 shares in the company, valued at $2,405,753.72. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 43,024 shares of the company’s stock in a transaction dated Thursday, March 29th. The stock was sold at an average price of $111.14, for a total transaction of $4,781,687.36. Following the completion of the transaction, the chief executive officer now owns 21,652 shares of the company’s stock, valued at approximately $2,406,403.28. The disclosure for this sale can be found here. In the last quarter, insiders sold 152,533 shares of company stock valued at $17,120,890. Insiders own 7.80% of the company’s stock.
About United Therapeutics
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.